Michael Gelband’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Michael Gelband’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,699	Closed	-$326K	–	2070
2023 Q4	$326K	Sell	7,699 -34,535	-82%	-$992K	﹤0.01%	1158
2023 Q3	$922K	Buy	42,234 +26,989	+177%	+$675K	0.01%	990
2023 Q2	$485K	Buy	+15,245	New	+$468K	﹤0.01%	1373
2021 Q2	–	Sell	-88,092	Closed	-$1.21M	–	2923
2021 Q1	$1.21M	Buy	88,092 +38,100	+76%	+$558K	0.02%	808
2020 Q4	$829K	Buy	+49,992	New	+$649K	0.01%	964

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Michael Gelband's CERE Position: Q1 2024 in Review

Michael Gelband sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 7,699 shares — an estimated $326K sold.

Michael Gelband first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $1.21M in Q1 2021. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

Michael Gelband reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Michael Gelband sold 7,699 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $326K.
Michael Gelband first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Michael Gelband's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.21M in Q1 2021.
210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.